Omecamtiv mecarbil is a novel, small-molecule, direct activator of cardiac myosin, the motor protein that causes cardiac contraction. It is being evaluated as a potential treatment of heart failure in both intravenous and oral formulations with the goal of establishing a new continuum of care for patients in both the in-hospital and outpatient settings.
DRUG DEVELOPMENT DECONSTRUCTOR MANIFESTO: : “Tell me how you read and I'll tell you who you are.” ― Martin Heidegger
Wednesday, September 4, 2013
Targeted failure of the week. Post No 99. Omecamtiv mecarbil
Omecamtiv mecarbil is a novel, small-molecule, direct activator of cardiac myosin, the motor protein that causes cardiac contraction. It is being evaluated as a potential treatment of heart failure in both intravenous and oral formulations with the goal of establishing a new continuum of care for patients in both the in-hospital and outpatient settings.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment